Asparia Glycomics is Other Pharmaceuticals and Biotechnology in Spain that focus on higher throughput business. Founded in 2016. They cover business area such as Provider, isotope label glycan, quantification software, reagent, glycan analysis, mass spectrometry, marketing, reference standard, kit, clinical diagnosis, quality control, biopharmaceutical, clinician, high precision, high throughput, exist solution.
Other Pharmaceuticals and Biotechnology
2016
( 8 years old in 2024 )
Higher Throughput
-
Paseo de Mikeletegi, 83
Floor 3, Lab 04
20009 San Sebastián
Spain
Private
Providerisotope label glycanquantification softwarereagentglycan analysismass spectrometrymarketingreference standardkitclinical diagnosisquality controlbiopharmaceuticalclinicianhigh precisionhigh throughputexist solution
* We use standard office opening hours in near Asparia Glycomics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Asparia Glycomics is Other Pharmaceuticals and Biotechnology business from Spain that founded in 2016 (8 years old in 2024), Asparia Glycomics business is focusing on Higher Throughput.
Asparia Glycomics headquarter office and corporate office address is located in Paseo de Mikeletegi, 83 Floor 3, Lab 04 20009 San Sebastián Spain.
Asparia Glycomics was founded in Spain.
In 2024, Asparia Glycomics is currently focus on higher throughput sector.
Above is snippet of Google Trends for "higher throughput" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Asparia Glycomics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
